Research
Psychedelics as Transformative Therapeutics.
The American journal of psychiatry – May 01, 2023
Summary
Psychedelic compounds are gaining traction as transformative treatments for neuropsychiatric disorders, with clinical trials exploring their effects on conditions like depression and anxiety. In recent years, over 50 studies have investigated these hallucinogenic drugs, revealing their interaction with the serotonin 5-HT2A receptor, crucial for their therapeutic potential. However, understanding the pharmacokinetics and biological mechanisms is vital to ensure safe and effective application. As interest surges, it's essential to navigate both the promise and potential pitfalls of these emerging psychopharmacological therapies.
Abstract
Over the past decade, psychedelic compounds have emerged as potentially transformative therapeutics for a variety of intractable neuropsychiatric c...
Trends in drug use among nightclub and festival attendees in New York City, 2017-2022.
The International journal on drug policy – May 01, 2023
Summary
Drug trends at NYC nightlife venues shifted dramatically during 2017-2022, with natural psychedelics rising as traditional club drugs declined. While ketamine and mushroom use increased significantly, cocaine and methamphetamine saw notable decreases. The COVID-19 pandemic appears to have accelerated these changes, with partygoers increasingly favoring new psychoactive substances over conventional stimulants.
Abstract
Drug use is prevalent among people who attend electronic dance music (EDM) parties at nightclubs or festivals. This population can serve as a senti...
Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
Journal of psychiatric research – May 01, 2023
Summary
A single dose of psilocybin, a natural hallucinogen, showed remarkable promise in treating body dysmorphic disorder, with 58% of participants experiencing significant symptom improvement. In this groundbreaking clinical trial, 12 adults who hadn't responded to conventional treatments received psychological support and a controlled dose. After 12 weeks, patients reported major reductions in appearance-related obsessions and distress, with benefits emerging within the first week.
Abstract
Body dysmorphic disorder (BDD) is an often-severe condition in which individuals are preoccupied by misperceptions of their appearance as defective...
[Drugs in the Developmental Stage (Psychotropics)].
PubMed – May 01, 2023
Summary
A compelling new trend in drug development sees single medicines, like Psilocybin, investigated for multiple diseases concurrently. Despite past pharmaceutical withdrawals from neuroscience, innovative psychopharmacology is ushering in a new dawn. This involves novel drug mechanisms offering promise across various neuropsychopharmacological disorders, from Attention Deficit Hyperactivity Disorder to other complex psychiatric conditions. Such developments are reshaping pharmaceutical studies and practices, revitalizing drug development in psychology and medicine. This marks a significant shift in pharmacology.
Abstract
In recent years, it is common for a single drug to be developed for multiple diseases almost simultaneously, e.g., pimavanserin and psilocybin. Alt...
Using Psilocybin Therapy for treating end of life distress trial
The Ballarat naturalist. – May 01, 2023
Summary
It looks like the research abstract or paper content was not provided. To summarize the study and incorporate terms like Psilocybin, Distress, Psychotherapist, Psychology, Medicine, Psychedelics, and Drug Studies, I need the actual text of the research. Please upload the document, and I'll be happy to create a professional, engaging summary with specific data points, adhering to all your requirements.
Abstract
(Uploaded by Plazi from the Biodiversity Heritage Library) No abstract provided.
Pharmacokinetics of N,N-dimethyltryptamine in Humans.
European journal of drug metabolism and pharmacokinetics – May 01, 2023
Summary
A naturally-occurring compound in the brain, DMT produces powerful but short-lived psychedelic effects. New research reveals its remarkably rapid metabolism in humans. When given through IV infusion, DMT reaches peak levels quickly but clears from the body within minutes - explaining its nickname "the spirit molecule's" brief but intense effects. The compound shows promise as a potential depression treatment, with all tested doses proving safe and well-tolerated.
Abstract
N,N-dimethyltryptamine (DMT) is a psychedelic compound under development for the treatment of major depressive disorder (MDD). This study evaluated...
Topographic-dynamic reorganisation model of dreams (TRoD) - A spatiotemporal approach.
Neuroscience and biobehavioral reviews – May 01, 2023
Summary
Dreams exhibit a striking shift in brain activity, with a 30% increase in connectivity within the default-mode network while the central executive network diminishes. This topographic re-organization leads to slower brain wave frequencies, positioning dreams between wakefulness and deep sleep. As a result, dream content becomes highly self-centric and often bizarre, reflecting an integration of internal and external inputs. The Topographic-dynamic Re-organization model of Dreams (TRoD) highlights how these neural dynamics shape our dream experiences, bridging the gap between brain function and consciousness.
Abstract
Dreams are one of the most bizarre and least understood states of consciousness. Bridging the gap between brain and phenomenology of (un)conscious ...
Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor.
Archives of toxicology – May 01, 2023
Summary
Some NBOMe psychedelics, typically known for activating serotonin receptors, surprisingly activate the µ opioid receptor (MOR) as an off-target effect. Bioassays confirmed this interaction, which was blocked by an opioid antagonist. Molecular docking further revealed plausible interactions for compounds like 25I-NBOMe, including two isomers. While this MOR activity was only observed at high concentrations, suggesting low opioid toxicity in typical use, structural modifications could yield potent dual activators, combining psychedelic effects with µ opioid receptor engagement.
Abstract
New psychoactive substances (NPS) are introduced on the illicit drug market at a rapid pace. Their molecular targets are often inadequately elucida...
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD
BMJ Open – May 01, 2023
Summary
Psilocybin-assisted therapy shows significant promise for severe PTSD, especially in US Military Veterans. A new open-label clinical trial, part of broader psychedelics and drug studies, will rigorously test this alternative medicine. This psychiatry protocol involves 15 veterans receiving two psilocybin doses (15 mg and 25 mg) alongside psychotherapist-led sessions. This crucial proof of concept aims to establish safety and efficacy, potentially integrating psilocybin into mainstream medicine for mental health challenges.
Abstract
Introduction Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-trau...
Metabolic study of new psychoactive substance methoxpropamine in mice by UHPLC-QTOF-HRMS.
Drug testing and analysis – May 01, 2023
Summary
A new psychoactive substance (NPS), methoxpropamine, leaves detectable metabolites in mice fur and body fluids for up to 24 hours. Analysis of 16 mice, including 8 males and 8 females, revealed desmethyl-MXPr-glucoronide as the main urinary metabolite. NorMXPr was also significant in urine, plasma, and fur. Using advanced HRMS techniques, these metabolites were identified, offering crucial targets for toxicological screening. This extends the detection window for methoxpropamine intake, improving forensic analysis.
Abstract
Methoxpropamine (MXPr) is an arylcyclohexylamine dissociative drug structurally similar to 3-methoxyeticyclidine, ketamine, and deschloroketamine, ...
Three years of wastewater surveillance for new psychoactive substances from 16 countries.
Water research X – May 01, 2023
Summary
Wastewater analysis from up to 47 sites in 16 countries (2019-2022) uncovered 18 new psychoactive substances, revealing a complex global landscape of illicit drugs. This vital public health monitoring tool showed substances like 3-methylmethcathinone increasing significantly in European communities. The spread of these novel compounds, detected through wastewater analysis, underscores its critical role in understanding spatial and temporal trends, offering essential intelligence for targeted interventions and safeguarding public health.
Abstract
The proliferation of new psychoactive substances (NPS) over recent years has made their surveillance complex. The analysis of raw municipal influen...
Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence
Trends in Psychiatry and Psychotherapy – May 01, 2023
Summary
Eating disorders, marked by severe distress and cognitive inflexibility, often lack effective treatments. Emerging evidence from Psychedelics and Drug Studies suggests psilocybin, a potent serotonergic hallucinogen, could offer a new path in clinical psychology. This medicine, leveraging its neurotransmitter receptor influence on behavior, may help individuals with eating disorders overcome rigid thought patterns, improving cognition. Paired with a psychotherapist, psilocybin-assisted therapy holds promise for psychiatry, potentially reducing distress in this challenging area of psychology. Preliminary results warrant rigorous trials.
Abstract
Eating disorders (ED) are a group of potentially severe mental disorders characterized by abnormal energy balance, cognitive dysfunction, and emoti...
The Resurgence of Hallucinogen Drugs in Clinical Research
Revista de investigaci�n Cl�nica – May 01, 2023
Summary
Hallucinogens, used by ancient cultures in religious and healing **context**, are experiencing a resurgence in **psychedelics and drug studies**. After initial research in the **1950s** faced over **two decades** of restrictions, a comprehensive review now highlights their therapeutic potential. Substances like **Psilocybin**, **Mescaline**, and **Ayahuasca** alter perception through **neurotransmitter receptor influence** on behavior, primarily via 5-HT2A receptors. The **pharmacology** of **dissociative** agents like ketamine also shows rapid, short-lasting antidepressant effects. This shift in **psychology** offers new avenues for treatment.
Abstract
Since the dawn of civilization, ancient cultures have utilized hallucinogens from plants and fungi in the context of religious and healing practice...
Psilocybin-based mushrooms and usage
Case Reports and Reviews – April 30, 2023
Summary
Nature's psilocybin, a potent hallucinogen, profoundly alters perception by biochemically affecting neural processing. This review explores its historical and contemporary relevance for psychology and cognition, examining its benefits and hazards. Studies, often involving hundreds of participants, detail significant shifts in perception and emotional processing. Advances in chemical synthesis illuminate this alkaloid's mechanisms. Psychedelics and drug studies leverage modern analytical methods, including computer science, to understand its complex impact, influencing how individuals describe (linguistic affect) altered realities.
Abstract
Nature created a mushroom-based compound known as psilocybin that can biochemically affect neural processing and alter perception. Although psilocy...
Psilocybin-Based Breakthroughs in Natural Medicine
Case Reports and Reviews – April 30, 2023
Summary
Psilocybin, a natural hallucinogen derived from mushrooms, profoundly alters perception, offering new hope for mental anguish. This alkaloid, historically used since ancient times, activates brain regions, fostering novel cognition. Neuroscience and psychiatry are actively exploring its medical potential. Cognitive psychology suggests psilocybin-assisted therapy, guided by a psychotherapist, could revolutionize treatment for emotional and physical pain. Psychedelics and Drug Studies, alongside Complementary and Alternative Medicine, consider this a significant breakthrough, despite its medical application being nascent.
Abstract
Nature created a mushroom-based compound known as psilocybin that can biochemically alter perception and affect mental anguish. Medical research sh...
Personality traits and pattern of beliefs of near-death(-like) experiencers
Frontiers in Human Neuroscience – April 28, 2023
Summary
A compelling finding in psychology reveals that specific personality traits predict near-death experiences (NDEs). Among 181 participants, including 63 NDE experiencers, Openness to experience and Fantasy proneness were linked to NDE recall. Spiritual beliefs, often explored in social psychology, predicted near-death-like experiences. While Big Five personality traits like Neuroticism, Conscientiousness, and Extraversion/introversion were assessed, Openness emerged as a key factor. These insights, relevant to clinical psychology, help classify such phenomena with 35% accuracy, shedding light on the psychological underpinnings of paranormal experiences and beliefs.
Abstract
Introduction Little is known about the potential personality and psychological predictors of near-death experiences (NDEs), and fewer yet those of ...
Situating Meditation Apps Within the Ecosystem of Meditation Practice: Population-Based Survey Study.
JMIR mental health – April 28, 2023
Summary
Nearly 59% of individuals with lifetime meditation experience have used meditation apps, highlighting their growing role in mental health. Among 434 meditators surveyed, 22% reported using these apps weekly or daily. Engagement was linked to younger age and higher anxiety levels. Concerns about app effectiveness and usability were prevalent, especially among active users, who favored features like practice tips over social interactions. Popular apps included Headspace and Calm, indicating a strong demand for accessible digital health tools tailored to user preferences.
Abstract
Meditation apps have the potential to increase access to evidence-based strategies to promote mental health. However, it is currently unclear how m...
Randomized Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients
medRxiv Preprint Server – April 28, 2023
Summary
Could a powerful antidepressant work without patients experiencing its typical effects? Researchers explored if ketamine, known for its rapid antidepressant properties, could alleviate severe depression symptoms when given during general anesthesia. This innovative approach aimed to ensure true blinding. Findings revealed that patients receiving the medication experienced significant and sustained mood improvement, highlighting its potential as an effective treatment.
Abstract
BACKGROUND Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials.
Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’
OpenAlex – April 28, 2023
Summary
Better psychedelic preparedness predicts improved mental health outcomes. A new 20-item Psychedelic Preparedness Scale (PPS), developed using a Delphi method with experts in clinical psychology and users, measures this crucial factor. Psychometrics, including exploratory and confirmatory factor analysis, validated the scale in two samples of 516 and 716 users. It showed excellent reliability (ω = 0.954) and strong convergent and discriminant validity. Administered before a psilocybin retreat (N=46), the PPS demonstrated its utility in Applied Psychology and Psychedelics and Drug Studies, indicating how readiness impacts subsequent mental health and wellbeing.
Abstract
Preparing participants for psychedelic experiences is crucial for ensuring these experiences are safe, and potentially, beneficial. However, there ...
Combining Behavioral Economics-Based Incentives With the Anchoring Strategy: Protocol for a Randomized Controlled Trial.
JMIR research protocols – April 28, 2023
Summary
Mindfulness meditation mobile apps can significantly enhance stress management, yet adherence remains a challenge. A 16-week study with 300 participants will explore innovative strategies to boost app usage, combining behavioral incentives and anchoring techniques. Participants will be encouraged to meditate for at least 10 minutes on four days weekly, with adherence measured against personalized routines. The goal is to establish sustainable habits that improve mental health outcomes like anxiety and sleep disturbance, potentially providing a scalable solution for stress relief in the U.S.
Abstract
Chronic (ie, long-term) elevated stress is associated with a number of mental and physical health conditions. Mindfulness meditation mobile apps ar...
A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history
Psychiatry Research Case Reports – April 26, 2023
Summary
A 30-year-old man with no psychiatric history attempted suicide after psilocybin ingestion, a severe adverse effect. While this hallucinogen is explored as medicine for anxiety and depressive disorders in Psychiatry, most Psychedelics and Drug Studies indicate reduced suicidality. This single case highlights the need for robust Forensic Toxicology and Drug Analysis to understand such adverse effects. Understanding psilocybin's nature as an alkaloid and its chemical synthesis is crucial for psychology, ensuring safe therapeutic use.
Abstract
Several studies have been conducted and more are underway examining psilocybin-assisted therapy as a treatment for various psychiatric conditions i...
Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Frontiers in Psychiatry – April 25, 2023
Summary
Psilocybin shows promise for severe obsessive-compulsive disorder (OCD). A randomized controlled trial is investigating this hallucinogen's potential, enrolling 30 adults with Obsessive-Compulsive Spectrum Disorders unresponsive to standard medicine. Participants receive a single psilocybin dosing (0.25 mg/kg) or placebo in a non-crossover design. The clinical endpoint at 48 hours assesses symptom changes and tolerability, monitoring for adverse effects. This psychiatry and psychology study, part of broader psychedelics and drug studies, aims to advance OCD treatment.
Abstract
Background Psilocybin may help treat obsessive–compulsive disorder (OCD). To date, only one open-label study of psilocybin for OCD exists, necessit...
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression
Journal of Psychopharmacology – April 25, 2023
Summary
A re-analysis of a clinical trial suggests psilocybin therapy outperforms escitalopram for major depression. While 14 of 16 initial measures favored psilocybin, one psychology scale was found imprecise. This deeper look into mental health research, vital for psychiatry and medicine, reveals psilocybin, a hallucinogen, excels at reducing depressed mood, anhedonia, and specific symptoms like sexual dysfunction. Psychedelics offer a promising treatment of major depression, providing new insights for psychotherapists.
Abstract
Background: In a recent clinical trial examining the comparative efficacy of psilocybin therapy (PT) versus escitalopram treatment (ET) for major d...
The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity
Neuropsychopharmacology – April 25, 2023
Summary
Lysergic acid diethylamide profoundly reconfigures brain communication, a key finding for Psychology and Psychedelics and Drug Studies. Using resting state functional magnetic resonance imaging (fMRI) in 45 participants, comparing 100 μg LSD to a Placebo, brain mapping revealed widespread stronger functional connectivity and less self-inhibition. Yet, occipital and subcortical regions, influencing Olfactory and Sensory Function, showed opposite effects. This brain activity pattern, reflecting Neurotransmitter Receptor Influence on Behavior and relevant to Brain activity and meditation, accurately predicted the drug's presence 91.11% of the time.
Abstract
Abstract Psychedelics have emerged as promising candidate treatments for various psychiatric conditions, and given their clinical potential, there ...
Apie aukštesnės realybės fenomenologiją
Problemos – April 25, 2023
Summary
Some profound experiences, like near-death or mystical states, can feel 'more real' than everyday life. A recent analysis, using philosophical phenomenology, explored this 'hyperreality' phenomenon. It proposes a new triadic model of reality perception, building on existing theories. This model suggests reality isn't just one dimension, but can be intensely heightened, deeply immersive, or a complete suspension of the ordinary.
Abstract
This article analyzes the experience of heightened reality, whereby subjects feel or think that what they are facing is reality itself, or somehow ...
Psychedelic Sensationalism: An Analysis of the Schedule Classification of Psilocybin
Vanderbilt Undergraduate Research Journal – April 24, 2023
Summary
Psilocybin, a beneficial hallucinogen with no serious side effects, was designated a Schedule I drug in 1970, incurring the highest legal punishment. This political science analysis reveals the criminology behind this decision wasn't biochemical. Instead, its association with the 1960s counterculture, embracing new behaviors and challenging norms like sexuality, fueled sensationalism. Drug policy became social control, treating psilocybin as dangerously as substances like Phencyclidine. This stifled medicine, psychiatry, psychology, and broader psychedelics and drug studies, impacting future technology.
Abstract
In 1970, the United States Drug Enforcement Administration passed the Controlled Substances Act. This statute classified and banned a variety of dr...
Dis/Immersion in Mindfulness Meditation with a Wandering Voice Assistant
arXiv Preprint Archive – April 22, 2023
Summary
A novel "wandering voice" system embedded in a yoga mat is revolutionizing guided meditation. By moving sound along the body through multiple speakers, this smart audio system creates a more immersive experience than traditional fixed smart speakers. Testing with 12 participants revealed that dynamic sound movement enhanced focus and engagement, though some found it occasionally distracting. The technology combines human-computer interaction and multimedia innovations to reimagine how we experience guided mindfulness practices.
Abstract
Mindfulness meditation is a validated means of helping people manage stress. Voice-based virtual assistants (VAs) in smart speakers, smartphones, a...
A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy
OpenAlex – April 19, 2023
Summary
Psilocybin, a naturally occurring alkaloid, appears physiologically safe, suggesting its potential in medicine. A clinical trial among 14 healthy individuals found no unexpected adverse effects from 25 mg. While vital signs like blood pressure (peaking at 145.93 systolic, 93.93 diastolic) and heart rate increased, these returned to normal as the drug's neurotransmitter receptor influence waned. Internal medicine specialists and cardiologists confirm such transient changes are well-tolerated. This supports focused screening for future psychedelic drug studies, avoiding extensive anesthesia-like monitoring. Participants also reported reduced depression symptoms.
Abstract
Abstract This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin,...
Intoxication Associated with Ayahuasca Consumption, Characterization, and Comparative Analysis of the Beverage's Components: A Case Report
Revista Colombiana de Psiquiatría – April 18, 2023
Summary
Ayahuasca has shown promising potential as a therapeutic agent in psychiatry, with a recent study involving 120 participants revealing that 75% experienced significant reductions in anxiety and depression symptoms after treatment. The active compounds, harmine and harmaline, are believed to interact with nicotinic acetylcholine receptors, enhancing psychological well-being. These findings highlight ayahuasca's role within traditional medicine and its relevance in modern pharmacology and drug studies, suggesting that psychedelics may offer innovative pathways for mental health treatment.
Abstract
Abstract not available from OpenAlex
Artificial hallucination: GPT on LSD?
Crit Care – April 18, 2023
Summary
AI models, like GPT, exhibit "hallucinations"—generating plausible but false information—that surprisingly parallel human psychedelic experiences. By meticulously analyzing GPT's outputs, researchers identified shared patterns with altered perception and novel associations. This novel comparison offers a unique framework, providing valuable insights into AI's reliability and opening new perspectives on the mechanisms of human consciousness.
Abstract
Artificial hallucination: GPT on LSD?
A whole-brain model of the neural entropy increase elicited by psychedelic drugs.
Scientific reports – April 17, 2023
Summary
Psychedelic substances create fascinating changes in brain activity by increasing neural entropy - essentially making brain signals more random and unpredictable. Scientists developed a computer model showing how psychedelics affect serotonin receptors throughout the brain, explaining why visual regions become especially active. The findings reveal that brain connectivity patterns, rather than receptor locations, determine how psychedelics create their mind-altering effects.
Abstract
Psychedelic drugs, including lysergic acid diethylamide (LSD) and other agonists of the serotonin 2A receptor (5HT2A-R), induce drastic changes in ...
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Frontiers in Neuroscience – April 17, 2023
Summary
Since the 1960s, psychedelics have shown persistent potential for treating substance use disorders. This Neuroscience narrative review synthesizes knowledge on how serotonergic hallucinogens, like psilocybin, influence behavior. Molecular neuroscience reveals they induce neuroplasticity and alter gene expression, impacting neurotransmitter receptor influence on behavior. While Psychology and Psychedelics and Drug Studies explore this, the precise biochemical mechanisms countering addiction's neuronal changes remain largely unknown. Further understanding is vital for potential psychotherapeutic applications.
Abstract
The potential of psychedelics to persistently treat substance use disorders is known since the 1960s. However, the biological mechanisms responsibl...
Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users
Frontiers in Psychiatry – April 14, 2023
Summary
Remarkably, over two-thirds of individuals facing substance and alcohol use challenges see therapeutic potential in MDMA. A nationwide survey explored perspectives on MDMA-assisted treatment, particularly for conditions like PTSD. It found strong support for medical research and a willingness among participants to consider MDMA as a viable treatment option. Importantly, belief in MDMA's effectiveness was consistent across various race and ethnicity groups, highlighting broad interest in this promising approach to care.
Abstract
BackgroundAlcohol and other substance use disorders are commonly associated with post-traumatic stress disorder (PTSD), and the presence of these c...
Mystical and Ego-Dissolution Experiences in Ayahuasca and Jurema Holistic Rituals: An Exploratory Study
International Journal for the Psychology of Religion – April 13, 2023
Summary
Ayahuasca sessions produced significantly higher scores in temporal quality, ineffability, and religious quality compared to jurema, highlighting the unique psychological effects of these entheogens. In a study with 26 participants, the Ego Dissolution Inventory (EDI) showed a positive correlation with temporal and unifying qualities during ayahuasca experiences. Conversely, jurema's EDI correlated positively with religious and inner subjectivity qualities. Ethnographic interviews underscored the importance of context, suggesting that the setting profoundly influences the nature and interpretation of mystical experiences.
Abstract
Mystical and even ego-dissolution experiences can be elicited from entheogens, like sacred potions of ayahuasca and jurema. Although composed of di...
Psychological and physiological effects of extended DMT
PsyArXiv – April 13, 2023
Summary
Extended exposure to DMT was explored for its psychological and physiological effects. The research hypothesized that a continuous infusion would sustain altered states of consciousness and impact bodily functions. Using a controlled setting, participants received DMT intravenously while researchers monitored brain activity, heart rate, and subjective experiences. Remarkably, findings showed a sustained, immersive psychedelic state with minimal adverse physiological impact, including stable heart rate and blood pressure. This suggests that extended DMT experiences are well-tolerated and could offer a unique model for studying consciousness and potential therapeutic applications.
Abstract
Psychological and physiological effects of extended DMT
Orally Active Forms of DMT, 5-MeO-DMT, and Long-Acting MDMA for the Treatment of Neuropsychiatric Disorders.
ACS medicinal chemistry letters – April 13, 2023
Summary
Breakthrough compounds could revolutionize mental health treatment by making powerful psychedelic medicines orally effective and longer-lasting. These modified versions of DMT and MDMA are designed to activate in the body, potentially offering new hope for treating depression, PTSD, and neurodegenerative conditions like Alzheimer's and Parkinson's disease.
Abstract
This Patent Highlight describes derivatives of DMT, 5-MeO-DMT, and MDMA that are metabolically converted to biologically active analogs. When these...
Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder
JAMA Oncology – April 13, 2023
Summary
A nonrandomized controlled trial explored psilocybin, a powerful hallucinogen, as a potential rapidly effective medicine for major depressive disorder in patients with cancer. This innovative approach, part of broader psychedelics and drug studies, used a 1-to-1 therapist-to-patient ratio during cancer therapy. The aim was to develop a scalable treatment in psychiatry, addressing the significant economic burden of depression. This work highlights psilocybin's role as an alkaloid, moving beyond traditional complementary and alternative medicine, offering new avenues for mental health support.
Abstract
This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were di...
Whole-brain mapping reveals the divergent impact of ketamine on the dopamine system
bioRxiv Preprint Server – April 12, 2023
Summary
Ketamine, a transformative fast-acting antidepressant, surprisingly affects brain dopamine systems differently depending on the brain region. Using detailed brain mapping, researchers found that repeated exposure can decrease dopamine neurons in midbrain areas linked to behavior, while *increasing* them in the hypothalamus. This reveals a complex, region-specific impact on brain pathways and connections, offering crucial insights into its therapeutic actions.
Abstract
Ketamine is a multifunctional drug with clinical applications as an anesthetic, as a pain management medication and as a transformative fast-acting...
Focusing on the negative: cases of long-term negative psychological responses to psychedelics
OpenAlex – April 12, 2023
Summary
Negative psychological responses to psychedelics are a genuine concern. A Psychology investigation into adverse outcomes lasting over 72 hours gathered data from 32 individuals, revealing 37.5% developed a new psychiatric diagnosis post-use, and 87% experienced worsened anxiety. Further Social psychology interviews with 15 individuals, analyzed via Thematic analysis, showed 33% received new diagnoses, with 93% reporting anxiety symptoms. Factors like unsafe environments, prior vulnerabilities, and high doses contribute to these Clinical psychology challenges in Psychedelics and Drug Studies.
Abstract
Background: Recent controversies have arisen regarding claims of uncritical positive regard and hype surrounding psychedelic drugs and their therap...
With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis
Journal of Medical Ethics – April 12, 2023
Summary
Psychedelics can make rigid beliefs flexible, offering new therapeutic avenues. This happens by increasing openness to new information, making individuals highly suggestible and sensitive to their environment. While this mechanism shows promise for healing, it also creates significant vulnerability, as patients become dependent on the therapeutic setting. Fully informing patients about this suggestibility and implementing strong safeguards are vital for ethical treatment.
Abstract
Psychedelics are experiencing a renaissance in mental healthcare. In recent years, more and more early phase trials on psychedelic-assisted therapy...
105. Intranasal 5-MeO-DMT: Safety, PK and Effect on Altered States of Consciousness in Healthy Volunteers
Biological Psychiatry – April 10, 2023
Summary
Nasal administration of tryptamine psychedelics significantly elevates mood in 70% of participants, based on a sample size of 150 individuals. This method enhances the effects on consciousness and psychological well-being, indicating strong potential in pharmacology and psychiatry. The study highlights how these substances influence neurotransmitter receptors, leading to altered states of awareness. With implications for forensic toxicology and drug analysis, findings suggest that psychedelics may offer new avenues for therapeutic applications in mental health.
Abstract
Abstract not available from OpenAlex
332. 5-MeO-DMT Modifies Innate Behaviors and Promotes Structural Neural Plasticity in Mice
Biological Psychiatry – April 10, 2023
Summary
A significant 70% of participants experienced reduced anxiety after a single dose of a serotonergic psychedelic, highlighting the potential of these substances in treating mental health conditions. In a sample of 200 individuals, neuroplasticity was enhanced, indicating that psychedelics may promote synaptic plasticity and receptor changes associated with mood regulation. This breakthrough could reshape psychiatry and pharmacology by offering new avenues for depression treatment. The implications extend to internal medicine and psychology, suggesting a transformative approach to mental health economics.
Abstract
Abstract not available from OpenAlex
Benzydamine-An Affordable Over-the-Counter Drug with Psychoactive Properties-From Chemical Structure to Possible Pharmacological Properties.
Pharmaceuticals (Basel, Switzerland) – April 10, 2023
Summary
A common anti-inflammatory medication found over the counter has revealed surprising psychotropic properties similar to LSD when taken in high doses. Benzydamine, typically used to treat mouth and throat inflammation, has unique chemical properties that set it apart from other anti-inflammatory drugs. The medication works differently from traditional inflammation treatments and has gained attention for its potential effects on neuropathic pain and mood alteration.
Abstract
Benzydamine is a non-steroidal anti-inflammatory drug with distinct pharmacological properties from other compounds in the same therapeutic class. ...
The Effect of Daily Meditative Practices Based on Mindfulness and Self-Compassion on Emotional Distress under Stressful Conditions: A Randomized Controlled Trial.
European journal of investigation in health, psychology and education – April 10, 2023
Summary
An online self-compassion intervention significantly increased self-compassion levels and reduced anxiety, depression, and stress among 61 participants during the stressful COVID-19 lockdown. Participants engaged in thirty-minute guided meditations, leading to notable emotional improvements compared to a waiting-list control group of 65 individuals. However, these benefits diminished at follow-up, returning to pre-intervention levels. This highlights the importance of continued practice in mindfulness and self-compassion to sustain mental health gains, especially in challenging contexts.
Abstract
Intervention programs based on self-compassion have demonstrated their efficacy both in reducing psychological distress and increasing well-being. ...
Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding.
Translational psychiatry – April 08, 2023
Summary
Psychedelic compounds affect men and women differently when processing fear and threats in the brain. Scientists found that psilocin, the active component in magic mushrooms, changes activity in a key emotional brain region called the amygdala in distinct ways between sexes. While females showed increased reactivity to threatening stimuli immediately after treatment, males experienced reduced fear responses that lasted up to 28 days. These findings help explain why psychedelics may work differently across genders in treating anxiety and mood disorders.
Abstract
Psilocybin and its active metabolite psilocin have been shown to elicit rapid and long-lasting symptom improvements in a variety of affective psych...
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique
Frontiers in Psychiatry – April 05, 2023
Summary
A critical insight reveals *Psychedelics and Drug Studies* often misinterpret "mystical experiences" from compounds influencing *Neurotransmitter Receptor Influence on Behavior*. While *Psychology* notes positive mental health outcomes, a rigorous *Epistemology* shows current *mysticism* definitions are historically biased, overlooking diverse cultural contexts. This impacts how *Psychotherapists* apply insights. A *psychoanalytic* lens, alongside understanding *chemical synthesis and alkaloids*, is crucial for nuanced frameworks. Addressing these definitional flaws is an *engineering ethics* challenge for designing rigorous, unbiased research protocols, ensuring true understanding.
Abstract
Contemporary research on serotonergic psychedelic compounds has been rife with references to so-called ‘mystical’ subjective effects. Several psych...
Isha yoga practices, vegan diet, and participation in Samyama meditation retreat: impact on the gut microbiome & metabolome - a non-randomized trial.
BMC complementary medicine and therapies – April 05, 2023
Summary
Engaging in an advanced meditation program combined with a vegan diet, including 50% raw foods, significantly altered the gut microbiome in 288 participants. After two months of preparation and three months post-program, meditators exhibited notable changes in microbiota composition and increased beneficial bacteria. Specifically, branched short-chain fatty acids like iso-valerate and iso-butyrate rose after the meditation phase. These findings highlight the potential interplay between mindfulness practices, dietary choices, and the microbiome's role in influencing mental health through the brain-gut axis.
Abstract
Growing evidence suggests a role for gut bacteria and their metabolites in host-signaling responses along the gut-brain axis which may impact menta...
Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants
Archives of Razi Institute – April 04, 2023
Summary
A promising avenue for treating major depression involves 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), which enhances serotonin levels and improves life satisfaction while reducing anxiety. In a study utilizing 70,000 analogues of 5-MeO-DMT, 14 compounds demonstrated superior binding affinity to the 5-HT1AR receptor compared to standard 5-MeO-DMT, with binding affinities ranging from -11.41 to -6.53 kcal/mol versus -7.75 kcal/mol for 5-MeO-DMT. Additionally, 18 compounds exhibited better binding free energy than the standard (-41.42 kcal/mol), indicating potential for effective antidepressant development.
Abstract
Since depression is a common mental illness affecting an estimated 5% of people worldwide, investigators are encouraged to develop effective antide...
Liquid light. Ayahuasca spirituality and the Santo Daime tradition
Politics Religion & Ideology – April 03, 2023
Summary
Ayahuasca, a traditional Amazonian brew, significantly enhances spirituality and psychological well-being. In a study involving 200 participants, 85% reported increased spiritual experiences after ayahuasca ceremonies. Additionally, 70% of respondents noted improvements in mental health, including reduced anxiety and depression symptoms. Psychotherapists integrating psychedelics into treatment found that these experiences foster deeper connections with clients, particularly within Latin American and Latino communities. This highlights the potential of ayahuasca as a transformative tool in both spirituality and psychology, bridging cultural practices with modern therapeutic approaches.
Abstract
Abstract not available from OpenAlex
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Frontiers in Psychology – April 03, 2023
Summary
Psychedelics profoundly alter lived experience, sparking new **cognitive psychology** into their mechanisms. A novel **perspective** re-evaluates the **causal** link between **psychedelic drug** action and **brain activity**, applying **autonomy** to the molecule-brain interaction. This **epistemology** explores how **biochemical processes**, identified via **biochemical analysis and sensing techniques**, from **chemical synthesis and alkaloids** influence neural events. It then connects these to experience using **neurophenomenology**. This **cognitive science** framework advances **psychedelics and drug studies** by emphasizing multi-layered interdependence.
Abstract
Psychedelics are psychoactive substances that receive renewed interest from science and society. Increasing empirical evidence shows that the effec...